Lexaria Bioscience Corp. (NASDAQ: LEXX) Emphasizes Oral Cannabinoid Delivery Benefits Following SARS-CoV-2 Study
The study is available for public viewing and is entitled “Cannabinoids Block Cellular Entry of SARS-CoV-2 and the Emerging Variants” (https://cnw.fm/Aq36i) Dr. Richard van Breeman, who headed the independent study, explained that smoking and vaping cannabinoids are ineffective against preventing SARS-CoV-2, whereas oral delivery methods are effective Lexaria has been studying and researching the oral delivery of compounds using its patented DehydraTECH(TM) technology, which enhances bioavailability and absorption, requiring less heat than smoking or vaping and leaving the cannabinoid compounds undamaged Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, commented on an independent January 10 study headed…

















